The CHMP’s November Verdict: Seven Approvals, Eleven Extensions, and a Post-Approval Evidence Burden That Sponsors Underestimate

Seventy-nine new medicines recommended for approval year-to-date through November. By the time the Committee for Medicinal Products for Human Use wrapped its November 9-12 session and recommended seven new medicines for marketing authorization alongside eleven extensions of existing indications, the EMA had maintained a high pace of regulatory activity through the year. The committee also confirmed two outright refusals, which is worth remembering: 79 positive opinions do not mean the bar dropped. But volume alone doesn’t tell sponsors what they actually need to know about operating inside the European regulatory system right now.

Three signals from this November session, read alongside the trajectory of the full 2026 calendar, reveal a pattern that clinical operations teams haven’t fully internalized: the CHMP is approving more, faster, and with more post-approval strings attached than in recent prior cycles. That combination should reframe how sponsors design their Phase III programs and, critically, how they budget for the decade of evidence generation that follows an EU authorization.

Momentum at the Top of the Funnel

The headline drug from November’s session is Aumseqa (aumolertinib), a third-generation EGFR inhibitor recommended for non-small cell lung cancer. Aumolertinib’s NSCLC data package supported a full positive opinion from the committee., which is increasingly what European reviewers demand before granting a full, unconditional authorization in oncology. The committee’s positive opinion for aumolertinib in oncology reflects the CHMP’s continued engagement with targeted therapies in this space.

That stabilization is itself a signal worth tracking. For sponsors developing next-generation targeted oncology agents, the CHMP’s willingness to issue positive opinions on mature OS data reflects a maturing reviewers’ posture, one that rewards sponsors who front-load survival follow-up into their pivotal designs rather than racing to file on surrogate endpoints and negotiating the rest post-approval. The eleven label extensions granted this session reinforce the same logic from the other direction: they represent drugs that already cleared the full authorization threshold and are now adding indications on top of established safety databases.

Compare this to 2024, when the EMA processed 120 marketing authorization applications and issued 113 positive opinions, with 46 representing new active substances. Through November 2026, the committee had recommended 79 new medicines, suggesting the pace of new medicine recommendations has accelerated. The pipeline is not thinning.

The Post-Approval Trap Sponsors Keep Walking Into

Here is the counterintuitive reality that the volume numbers obscure: a CHMP positive opinion is not the finish line for clinical evidence generation. For a growing proportion of approvals, it is the starting pistol for a mandatory post-authorization evidence program that will consume significant resources for years. The EMA’s conditional marketing authorization framework, with its evolving PASS requirements under the EU pharmacovigilance framework,, now imposes more precisely defined data-collection obligations than sponsors typically model into their go-to-market plans.

The EMA finalized the real-world data chapter of its Data Quality Framework on March 27, 2026, adopted by the CHMP on March 16, 2026. That document, formally titled “Data Quality Framework for EU medicines regulation: application to real-world data (RW-DQF),” creates specific quality standards that RWD submitted to satisfy PASS obligations must now meet. The framework addresses data provenance, fitness-for-purpose assessments, and bias documentation in ways that make informal registry data or opportunistic healthcare database pulls increasingly insufficient for European regulators. Sponsors who assumed that post-authorization evidence generation in the EU could be handled with low-cost observational work are now discovering that the methodological overhead rivals a formal Phase IIIb.

The CHMP’s two confirmed refusals this November are equally instructive. When the committee confirms a negative opinion, it typically means the sponsor either failed to respond adequately to outstanding questions or submitted re-examination arguments that the committee found unconvincing. In 2024, the CHMP issued six negative opinions against 113 positive ones. That ratio, roughly 5%, suggests the committee is highly selective about what it refuses outright rather than holding in a request-for-information loop. Sponsors who reach a confirmed refusal have usually been telegraphed a signal earlier in the review cycle that they misread or chose to contest. The lesson is not that the EMA is lenient. It is that the EMA front-loads its skepticism into the review dialogue, and sponsors who treat scientific advice meetings as optional courtesies are the ones who end up at a re-examination hearing.

What This Means for the People Running the Trials

For clinical operations teams, the November CHMP session and the broader 2026 approval trajectory carry three operational implications that are easy to miss when the news cycle focuses on the positive opinion count.

First, the eleven indication extensions granted this session represent approved drugs re-entering the evidence-generation cycle in new populations. Each extension carries its own PASS obligations and, under the updated EMA conditional marketing authorization framework, potentially its own conditional timeline. CROs and site networks that have been building European post-authorization study infrastructure are positioned to absorb this work. Sponsors who have not developed an integrated Phase IIIb and PASS execution model will find themselves outsourcing piecemeal to vendors with no institutional knowledge of the original Phase III dataset, which creates reconciliation problems when regulators ask how post-approval findings relate to pivotal trial subgroups.

Second, the EMA’s RW-DQF, finalized earlier this year, shifts the methodological burden of RWE generation squarely onto sponsors at the protocol design stage rather than at the analysis stage. Under the new framework, the fitness-for-purpose assessment for any real-world data source must be documented before data collection begins, not retrofitted after the dataset is assembled. Sponsors designing post-approval registries for drugs that received CHMP positive opinions in November 2026 need to be building those data quality justifications now, in the same project cycle as the marketing authorization file, not in a separate workstream that kicks off after the European Commission grants the license.

Third, the accelerated assessment and priority medicine designation pathways the EMA has developed and continued to refine compress pre-approval timelines in ways that transfer pressure directly onto post-approval programs. When a drug reaches patients faster, the confirmatory evidence generation that would otherwise have been completed before filing must be executed in the real-world commercial setting. That is not a problem unique to Europe. But the EMA’s RW-DQF now specifies the standard to which that confirmatory work will be held, and the standard is materially higher than what most sponsors modeled before March 2026.

The 108 positive opinions the CHMP had issued year-to-date through November’s session, including 79 new medicines recommended for approval,, tell a story of a regulatory committee operating at genuine capacity with genuine rigor. But the approvals that land on the wrong side of the EMA’s post-authorization evidence requirements in 2027 and 2028 will trace their problems back to decisions made in protocol design offices right now, not to anything the CHMP did in November. Sponsors who file early confirmatory PASS studies under the RW-DQF’s data provenance standards may help shape how regulators assess evidence quality for subsequent submissions in the same therapeutic area.

References

1. European Medicines Agency, “Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026”
2. Syenza News, “EMA Monthly Statistics Report, July 2026: Negative Opinions and Decision Data”
3. Becaris Publishing, “EMA Publishes Final Real-World Data Chapter of EU Data Quality Framework”
4. European Medicines Agency, “Conditional Marketing Authorisation”
5. European Medicines Agency, “Adaptive Pathways”